Higher Event Rate of T2DM in Polycystic Ovary Syndrome

Share this content:
Higher Event Rate of T2DM in Polycystic Ovary Syndrome
Higher Event Rate of T2DM in Polycystic Ovary Syndrome

THURSDAY, Aug. 31, 2017 (HealthDay News) -- Women with polycystic ovary syndrome (PCOS) have a higher event rate of type 2 diabetes (T2D), with diagnosis at a younger age, according to a study published online Aug. 29 in the Journal of Clinical Endocrinology & Metabolism.

Katrine Hass Rubin, Ph.D., from the University of Southern Denmark in Odense, and colleagues conducted a national register-based study involving patients with PCOS (PCOS Denmark and embedded cohort [PCOS OUH]) and a control population without T2D. A total of 1,162 premenopausal women were included in PCOS OUH, while PCOS Denmark included 18,477 women with PCOS; three age-matched controls were included for each woman (54,680).

The researchers found that during a median follow-up of 11.1 years, the hazard ratio for development of T2D was 4.0 in PCOS Denmark, with a total event rate of 8.0 versus 2.0 per 1,000 patient years in PCOS Denmark versus controls. The median age at diagnosis of T2D was 31 and 35 years in PCOS Denmark and controls, respectively. Positive associations were seen for body mass index, hemoglobin A1c, fasting blood glucose, two-hour blood glucose, homeostasis model assessment of insulin resistance, and triglycerides with T2D; a negative association was seen for higher number of births with T2D.

"The event rate of T2D was higher in PCOS compared to controls and T2D was diagnosed at a younger age," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »